Cycleron Ther Rg

Cycleron Therapeutics, Inc. is a clinical‑stage biopharma developing phase‑II soluble guanylate cyclase (sGC) stimulators—Olinciguat for cardiovascular disease and Praliciguat for rare kidney disease—backed by a strategic license with Akebia and headquartered in Cambridge, MA.

Headquarters: United States (USA)

Cycleron Ther Rg Logo
Company Profile
  • Employees: 1
  • HQ: Cambridge
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
CYCN Cycleron Ther Rg
Cap: 0.0B
EQUITY NMS USD US23255M1053 Active
📈
Home Login